NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Price, News & Analysis $1.33 -0.03 (-2.21%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.30▼$1.3750-Day Range$1.09▼$1.4852-Week Range$0.62▼$2.31Volume321,924 shsAverage Volume1.22 million shsMarket Capitalization$167.26 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Atossa Therapeutics alerts: Email Address Atossa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside332.3% Upside$5.75 Price TargetShort InterestBearish10.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.22) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.50 out of 5 starsMedical Sector870th out of 910 stocksPharmaceutical Preparations Industry406th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atossa Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.23% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Atossa Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 2.0 News and Social Media Coverage News SentimentAtossa Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atossa Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions.Read more about Atossa Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.22) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atossa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Atossa Therapeutics Stock (NASDAQ:ATOS)Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesSeptember 4 at 4:09 AM | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average of $1.38September 3, 2024 | globenewswire.comAtossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 29, 2024 | msn.com2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%August 28, 2024 | globenewswire.comAtossa Therapeutics Granted Additional Patent Protection for EndoxifenAugust 22, 2024 | finance.yahoo.comAtossa and Quantum Leap dose first subject in breast cancer therapy trialAugust 21, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerAugust 21, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 20, 2024 | globenewswire.comAtossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public RelationsAugust 12, 2024 | globenewswire.comAtossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 22, 2024 | globenewswire.comAtossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast CancerJuly 11, 2024 | investorplace.com3 Dirt-Cheap Drug Developers With Blockbuster PotentialJuly 3, 2024 | investorplace.com3 Penny Stock Moonshots with 300%+ Upside Potential by 2025July 2, 2024 | proactiveinvestors.comAtossa Therapeutics names Heather Rees as CFOJuly 2, 2024 | globenewswire.comAtossa Therapeutics Appoints Heather Rees as Chief Financial OfficerJune 28, 2024 | globenewswire.comAtossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerJune 17, 2024 | globenewswire.comAtossa Set to Join Russell 3000® Index Effective June 28, 2024See More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees8Year Founded2009Price Target and Rating Average Stock Price Target$5.75 High Stock Price Target$6.25 Low Stock Price Target$5.00 Potential Upside/Downside+332.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.13% Return on Assets-32.28% Debt Debt-to-Equity RatioN/A Current Ratio14.35 Quick Ratio14.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book2.08Miscellaneous Outstanding Shares125,757,000Free Float116,199,000Market Cap$167.26 million OptionableOptionable Beta1.21 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 73)M.D., Ph.D., Chairman, CEO & President Comp: $1.21MMs. Heather Rees CPA (Age 51)Senior VP of Finance & Principal Accounting Officer Comp: $520.64kMs. Delly Behen P.H.R.Senior Vice President of Administration & HRMr. Eric Van ZantenVice President of Investor & Public RelationsDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerKey CompetitorsSonoma PharmaceuticalsNASDAQ:SNOAAB Corporate Bond ETFNASDAQ:EYEGTetraphase PharmaceuticalsNASDAQ:TTPHApplied TherapeuticsNASDAQ:APLTHumacyteNASDAQ:HUMAView All CompetitorsInsiders & InstitutionsXTX Topco LtdBought 24,665 shares on 8/12/2024Ownership: 0.020%Renaissance Technologies LLCBought 164,540 shares on 8/9/2024Ownership: 1.233%Rhumbline AdvisersBought 135,118 shares on 8/1/2024Ownership: 0.107%Bank of New York Mellon CorpBought 399,041 shares on 7/26/2024Ownership: 0.327%Jonathan FinnBought 25,000 shares on 4/10/2024Total: $44,250.00 ($1.77/share)View All Insider TransactionsView All Institutional Transactions ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Therapeutics' stock was trading at $0.88 at the start of the year. Since then, ATOS shares have increased by 51.1% and is now trading at $1.33. View the best growth stocks for 2024 here. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its earnings results on Monday, August, 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. When did Atossa Therapeutics' stock split? Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. Who are Atossa Therapeutics' major shareholders? Top institutional shareholders of Atossa Therapeutics include Renaissance Technologies LLC (1.23%), Bank of New York Mellon Corp (0.33%), Rhumbline Advisers (0.11%) and XTX Topco Ltd (0.02%). View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD) and Biopharmx (BPMX). This page (NASDAQ:ATOS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATOS Stock Alerts